Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer & Jayne M. Ga...
October 22 2020 - 7:00AM
Business Wire
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the
expansion of its leadership team with the appointments of David S.
Ege, Ph.D., as Executive Vice President, Chief Technology Officer
(CTO) and Jayne M. Gansler as Executive Vice President, Chief
People Officer (CPO).
“Supported by our highly positive SER-109 Phase 3 results, we
are expanding our capabilities and strengthening the Seres team as
we move towards what we expect to be the first-ever FDA-approved
microbiome therapy. We have taken meaningful steps to prepare for
our anticipated growth into a commercial-stage enterprise. Earlier
this year, we appointed Lisa von Moltke, M.D., FCP, as Seres’ Chief
Medical Officer and Terri Young, Ph.D., R.Ph., as Chief Commercial
and Strategy Officer, and we are pleased to now add two additional
highly accomplished professionals to Seres’ executive team. Dave’s
experience successfully leading the manufacturing of prominent
pharmaceuticals, including Keytruda®, will be vital as we look
ahead to the expected commercialization of SER-109. Jayne has held
critical roles building global biopharmaceutical companies and this
experience will be central to attracting top talent to Seres, an
effort which is well underway. I am honored to work with such a
talented and diverse team,” said Eric D. Shaff, President and Chief
Executive Officer of Seres.
Mr. Shaff continued: “I also want to take this opportunity to
express our deep appreciation to John Aunins, Ph.D. John has led
Seres’ manufacturing efforts since soon after the company was
formed, and he has been critical in building our field-leading CMC
capabilities in this new therapeutic modality. We are pleased that
John will continue to support Seres in a Senior Advisor
capacity.”
Dr. Ege brings to the role of CTO more than 15 years of
experience in the pharmaceutical industry with a focus on
manufacturing and developing vaccines and biologics. He joins Seres
after an extensive career at Merck, where he worked on a number of
breakthrough, novel products with complex manufacturing. Dr. Ege
joined Merck in 2003 and served in a variety of technical and
leadership roles in R&D and manufacturing. He was most recently
Global Lead for Digital Strategy in Merck’s Manufacturing Division,
in charge of driving business optimization, leading digital
innovation, and helping advance products to market. Dr. Ege also
held roles as Executive Director of Vaccines & Biologics
Manufacturing and Head of Commercial Manufacturing Operations
during his time at Merck. Dr. Ege graduated summa cum laude from
Princeton with a BSE in chemical engineering and earned his Ph.D.
in chemical engineering from the University of Pennsylvania.
Ms. Gansler brings to the newly created role of CPO more than 25
years of experience leading global human resources organizations in
the biotechnology, pharmaceutical and medical device industries.
Prior to joining Seres, Ms. Gansler was Senior Vice President, Head
of Human Resources at ARIAD Pharmaceuticals and served as a key
leader during a time of significant change that included the sale
and integration of ARIAD with Takeda Pharmaceuticals. She served as
Senior Vice President, Global Head of Human Resources for Genzyme,
a Sanofi Company, following Sanofi’s acquisition of Genzyme
Corporation and led the integration and rebuilding of the HR
strategy for Genzyme, a Sanofi Company. Ms. Gansler’s strong
business acumen and relationship-building skills helped lead
Genzyme to be recognized by Fortune Magazine as one of the 100 Best
Companies to Work For. Prior to joining Genzyme, Jayne began her
career at Johnson & Johnson where she held various senior human
resources roles. She earned her B.A. in human resource management
and labor relations from the University of Massachusetts,
Amherst.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
multifunctional bacterial consortia that are designed to
functionally interact with host cells and tissues to treat disease.
Seres’ SER-109 program achieved the first-ever positive pivotal
clinical results for a targeted microbiome drug candidate and has
obtained Breakthrough Therapy and Orphan Drug designations from the
FDA. The SER-109 program is being advanced for the treatment of
recurrent C. difficile infection and has potential to become a
first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287
program has obtained Fast Track and Orphan Drug designations from
the FDA and is being evaluated in a Phase 2b study in patients with
active mild-to-moderate ulcerative colitis. Seres is developing
SER-401 in a Phase 1b study in patients with metastatic melanoma,
SER-301 for ulcerative colitis and SER-155 to prevent mortality due
to gastrointestinal infections, bacteremia and graft versus host
disease. For more information, please visit
www.serestherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201022005191/en/
PR Contact Lisa Raffensperger
lisa@tenbridgecommunications.com IR Contact Carlo Tanzi,
Ph.D. ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Sep 2023 to Sep 2024